全文获取类型
收费全文 | 2739篇 |
免费 | 197篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 82篇 |
妇产科学 | 26篇 |
基础医学 | 141篇 |
口腔科学 | 63篇 |
临床医学 | 279篇 |
内科学 | 531篇 |
皮肤病学 | 30篇 |
神经病学 | 33篇 |
特种医学 | 131篇 |
外国民族医学 | 1篇 |
外科学 | 164篇 |
综合类 | 468篇 |
预防医学 | 590篇 |
眼科学 | 42篇 |
药学 | 226篇 |
中国医学 | 32篇 |
肿瘤学 | 141篇 |
出版年
2023年 | 29篇 |
2022年 | 60篇 |
2021年 | 89篇 |
2020年 | 69篇 |
2019年 | 80篇 |
2018年 | 50篇 |
2017年 | 63篇 |
2016年 | 92篇 |
2015年 | 86篇 |
2014年 | 160篇 |
2013年 | 173篇 |
2012年 | 182篇 |
2011年 | 220篇 |
2010年 | 168篇 |
2009年 | 123篇 |
2008年 | 97篇 |
2007年 | 152篇 |
2006年 | 127篇 |
2005年 | 122篇 |
2004年 | 118篇 |
2003年 | 106篇 |
2002年 | 90篇 |
2001年 | 64篇 |
2000年 | 71篇 |
1999年 | 50篇 |
1998年 | 47篇 |
1997年 | 34篇 |
1996年 | 22篇 |
1995年 | 24篇 |
1994年 | 32篇 |
1993年 | 19篇 |
1992年 | 22篇 |
1991年 | 15篇 |
1990年 | 29篇 |
1989年 | 18篇 |
1988年 | 21篇 |
1987年 | 8篇 |
1986年 | 16篇 |
1985年 | 8篇 |
1984年 | 2篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1981年 | 7篇 |
1980年 | 4篇 |
1979年 | 2篇 |
1978年 | 5篇 |
1977年 | 2篇 |
1975年 | 3篇 |
1974年 | 2篇 |
1971年 | 1篇 |
排序方式: 共有2995条查询结果,搜索用时 109 毫秒
1.
目的:探讨门脉期双源CT多个定量参数与胃腺癌病理分化程度及HER2的相关性。方法: 回顾性分析2018年7月至2019年4月间于陕西省人民医院行双源CT双能量扫描的48例经胃镜活检(21例)或手术病理证实(27例)的胃腺癌及30例正常胃的影像学资料,其中27例HER2指标明确,通过西门子第二代双源CT扫描获得静脉期双能量图像,利用syngo.via软件获得曲线斜率、门脉期碘浓度、标准化碘浓度;将患者分为胃腺癌与正常胃壁组,高、中、低分化胃腺癌组,HER2阳性组(+,++,+++)与HER2阴性组(-)。统计学方法采用Kappa一致性检验、ROC曲线法、两独立样本t检验及方差分析。结果:活检与术后病理结果具有较强的一致性(Kappa系数为0.701),两者无明显差异;胃腺癌与正常胃壁两组间能谱曲线斜率(1.35±0.24、2.19±0.71)及标准化碘浓度(0.31±0.079、0.54±0.157)均具有统计学意义(P<0.05),曲线下面积分别为0.992、0.919;低分化、中分化及高分化胃腺癌能谱曲线斜率值(3.07±0.67,2.63±0.57,2.01±0.39)组间及组内差异均具有统计学意义(P<0.05),低分化、中分化及高分化胃腺癌门脉期标准化碘浓度(0.60±0.167,0.52±0.089,0.36±0.039)组间差异具有统计学意义(P<0.05),中分化组与低分化组差异无统计学意义(P>0.05),高分化组与中、低分化组均具有统计学差异(P<0.05)。HER2阳性组与阴性组的能谱曲线斜率及标准化碘浓度值无统计学差异(P>0.05)。结论:能谱曲线斜率及门脉期标准化碘浓度值有助于对胃腺癌进行诊断并推测病理分化程度;双源CT定量参数与免疫组化指标HER2无相关性。 相似文献
2.
目的研究鸦胆子油软胶囊联合SOX方案(奥沙利铂+替吉奥)治疗晚期结直肠癌的临床疗效。方法选取2018年8月-2019年8月在郑州大学附属洛阳中心医院治疗的80例晚期结直肠癌患者,所有患者随机分为对照组和治疗组,每组各40例。对照组患者入院后给予SOX方案治疗,第1~14天给予注射用奥沙利铂,推荐剂量130 mg/m^2,溶于500 mL 5%葡萄糖溶液中,输注时间小于3h;第1~21天口服替吉奥胶囊,1粒/次,2次/d。治疗组在对照组基础上口服鸦胆子油软胶囊,4粒/次,3次/d。21 d为1个治疗疗程,两组患者接受治疗3个疗程。观察两组的临床疗效,比较Karnofsky(KPS)评分、生活质量(QOL)评分及血清癌胚抗原(CEA)、基质金属蛋白酶(MMP)-2和MMP-9水平。结果经过治疗后,治疗组客观缓解率(ORR)和疾病控制率(CBR)显著高于对照组(P<0.05)。治疗后,两组患者KPS评分和QOL评分显著升高(P<0.05),且治疗组KPS评分和QOL评分升高程度较大(P<0.05)。治疗后,两组CEA、MMP-2和MMP-9水平显著降低(P<0.05);并且治疗组降低较多(P<0.05)。治疗组胃肠道反应、血小板减少、白细胞减少和转氨酶升高等不良反应发生率明显低于对照组(P<0.05)。结论鸦胆子油软胶囊联合SOX方案治疗晚期结直肠癌具有较好的治疗效果,能够提高患者生活质量,降低肿瘤标志物水平,安全性较高,值得在临床上推广应用。 相似文献
3.
目的探讨不同程度碘对比剂后急性肾损伤的危险因素及其转归预后。方法筛选2016年4月1日至2019年8月31日于重庆医科大学附属第三医院住院期间发生碘对比剂后急性肾损伤(PC-AKI)的患者,按照急性肾损伤分层标准将其分为非严重损伤组(A组)和严重损伤组(B组),从基本人口学资料、基础疾病、药物使用情况、转归预后等方面分析两组患者的特点及差异。结果 1 920例患者中发生PC-AKI者90例,其中A组72例(80.00%),B组18例(20.00%),B组中最终需肾脏替代治疗(血液透析)干预者11例(12.22%)。A组与B组间一般情况、基础肾功能、碘对比剂的使用以及联用肾毒性药物、静脉水化量等观察指标无统计学差异。B组合并慢性疾病者更多,其中冠心病(55.56%vs 29.17%)、心肌梗死(27.78%vs 5.56%)患病率差异具有统计学意义(P<0.05),行血液透析的患者第一诊断为心肌梗死者占45.45%。65.85%的患者在使用对比剂后10 d内肌酐仍高于基线,54.54%的透析患者在出院时仍需透析治疗,81.81%的透析患者出院时死亡或放弃治疗。结论合并冠心病、心肌梗死的患者更容易发生严重PC-AKI,当合并这些疾病的患者使用碘对比剂时,临床医师应密切关注其肾功能的变化。PC-AKI的肾功转归较差,发生PC-AKI后需透析治疗的患者往往预后不良。 相似文献
4.
《European journal of surgical oncology》2019,45(11):2090-2095
BackgroundWe sought to identify treatment disparities existing prior to publication of the 2015 American Thyroid Association Management Guidelines in order to identify patients with papillary thyroid cancer (PTC) at risk for receiving inadequate treatment.MethodsPatients diagnosed with PTC from 2011 to 2013 were identified using Surveillance, Epidemiology and End Results database. High-risk disease was defined as T4, N1, or M1. Chi-square tests compared characteristics of patients with and without high-risk disease and characteristics of high-risk patients who did and did not receive radioactive iodine ablation (RAI). Likelihoods of having high-risk disease, of receiving RAI, and of cause-specific death were calculated using regression analyses.ResultsSample included 32,229 individuals; 7894 (24.5%) had high-risk disease. Mean age was 50.0 years, 24,815 (77.0%) were female, and 21,318 (66.2%) were white. Odds of high-risk disease were greater among males (OR:2.04; 95% CI:1.92–2.16), Hispanics (OR:1.67; 95% CI:1.56–1.79) and Asians (OR:1.49; 95% CI:1.37–1.62), and uninsured (OR:1.24; 95% CI:1.07–1.43), and lower among patients ages 45–64 (OR:0.57; 95% CI:0.53–0.60), and ≥65 years (OR:0.54; 95% CI:0.50–0.59), and Blacks (OR:0.46; 95% CI:0.40–0.53). Most (69.3%) high-risk patients received RAI. Odds of receiving RAI were lower among patients age ≥65 years (OR:0.67; 95% CI:0.58–0.77), uninsured (OR:0.52; 95% CI:0.41–0.67), or with Medicaid (OR:0.58; 95% CI:0.50–0.69). RAI use reduced the risk of cause-specific mortality (HR:0.29; 95% CI:0.18–0.47).ConclusionKnowledge of these treatment disparities will allow recognition of groups at risk for high-risk disease and receiving inadequate treatment. 相似文献
5.
《European journal of surgical oncology》2020,46(5):754-762
With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one-size-fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects.This review considers the evidence base for the benefits of using RAI in the primary and recurrent setting as well as the side-effects and risks from RAI treatment. By considering the pros and cons of adjuvant therapy we present an oncologic surgical perspective on selection of treatment for patients, both following pre-operative diagnostic biopsy and in the setting of a post-operative diagnosis of malignancy. 相似文献
6.
Romain Tartse Paolo A. Sossi Frdric Moynier 《Proceedings of the National Academy of Sciences of the United States of America》2021,118(12)
Rocks from the lunar interior are depleted in moderately volatile elements (MVEs) compared to terrestrial rocks. Most MVEs are also enriched in their heavier isotopes compared to those in terrestrial rocks. Such elemental depletion and heavy isotope enrichments have been attributed to liquid–vapor exchange and vapor loss from the protolunar disk, incomplete accretion of MVEs during condensation of the Moon, and degassing of MVEs during lunar magma ocean crystallization. New Monte Carlo simulation results suggest that the lunar MVE depletion is consistent with evaporative loss at 1,670 ± 129 K and an oxygen fugacity +2.3 ± 2.1 log units above the fayalite-magnetite-quartz buffer. Here, we propose that these chemical and isotopic features could have resulted from the formation of the putative Procellarum basin early in the Moon’s history, during which nearside magma ocean melts would have been exposed at the surface, allowing equilibration with any primitive atmosphere together with MVE loss and isotopic fractionation.Returned samples of basaltic rocks from the Moon provided evidence decades ago that the Moon is depleted in volatile elements compared to the Earth (1), with lunar basalt abundances of moderately volatile elements (MVEs) being ∼1/5 that of terrestrial basalt abundances for alkali elements and ∼1/40 for other MVE, such as Zn, Ag, In, and Cd (2). The theme of lunar volatiles thus seemed settled. Yet, the unambiguous detection in 2008 of lunar indigenous hydrogen and other volatile elements, such as F, Cl, and S in pyroclastic glasses (3), heralded a new era of research into lunar volatiles, overturning the decades-old paradigm of a bone-dry Moon (e.g., refs. 4 and 5). Here, we define volatile elements as those with 50% condensation temperatures below these of the major rock-forming elements Fe, Mg, and Si (6). This paradigm shift was accompanied by new measurements of volatile stable isotope compositions (e.g., H, C, N, Cl, K, Cr, Cu, Zn, Ga, Rb, and Sn) in a wealth of bulk lunar samples (7–18) and in the mineral phases and melt inclusions they host (19–28). These studies have shown that the stable isotope compositions of most MVEs (e.g., K, Zn, Ga, and Rb) are enriched in their heavier isotopes with respect to the bulk silicate Earth (BSE) (9, 11, 13–15, 17). Such heavy isotope enrichment is associated with elemental depletion, which has been variously attributed to liquid–vapor exchange and vapor loss from the protolunar disk (17, 18), incomplete accretion of MVEs during condensation of the Moon (13, 29, 30), and degassing of these elements during lunar magma ocean crystallization (9, 11, 14, 15, 25, 31). Almost all these hypotheses have typically assumed that the MVE depletions and associated MVE isotope fractionations are relevant to the whole Moon. However, our lunar sample collections are biased, as all Apollo and Luna returned samples come from the lunar nearside from within or around the anomalous Procellarum KREEP Terrane (PKT) region (e.g., ref. 32), where KREEP stands for enriched in K, REEs, and P. Barnes et al. (26) proposed that the heavy Cl isotope signature measured in KREEP-rich Apollo samples resulted from metal-chloride degassing from late-stage lunar magma ocean melts in response to a large crust-breaching impact event, spatially associated with the PKT region, which facilitated exposure of these late-stage melts to the lunar surface. Here, we further investigate whether a localized impact event could have been responsible for the general MVE depletion and heavy MVE isotope enrichment measured in lunar samples. 相似文献
7.
8.
9.
目的观察~(125)I粒子胆管腔内联合瘤体内植入治疗不可切除胰头癌(PHC)的效果。方法回顾性分析72例不可切除PTH患者的临床资料,其中37例接受胆管腔内联合瘤体内植入~(125)I粒子治疗(~(125)I组),35例接受腹腔镜姑息性手术(PS组),对比2组术后肝功能、并发症、中位生存时间及截止随访终点时生存率。结果与术前比较,2组术后1、3及6个月时血清总胆红素、丙氨酸氨基转移酶及天门冬氨酸氨基转移酶水平均降低,白蛋白水平均升高,且术后3、6个月时~(125)I组较PS组更为显著(P均0.05)。PS组术后并发症发生率为28.57%(10/35),~(125)I组为21.62%(8/37),组间差异无统计学意义(P=0.496)。PS组患者中位生存时间为9个月,~(125)I组为11个月,组间差异有统计学意义(P=0.041)。结论胆管腔内联合瘤体内植入~(125)I粒子可有效缓解PHC所致胆管梗阻症状,延长患者生存期。 相似文献
10.
~(125)I粒子植入组织间近距离治疗恶性肿瘤发展迅速,已逐渐用于治疗前列腺癌、头颈部恶性肿瘤、颅内恶性肿瘤、肺癌、肝癌等多种恶性实体肿瘤,取得了较好的效果,但尚存在学科定位不明、从业者资质混杂、临床应用随意性大、操作技术不统一等诸多问题。本文对~(125)I粒子植入组织间近距离治疗恶性实体瘤的应用现状以及存在的问题进行综述。 相似文献